Turn Therapeutics (NASDAQ:TTRX) Stock Rating Upgraded by Wall Street Zen

Turn Therapeutics (NASDAQ:TTRX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

A number of other research analysts have also recently commented on the stock. LADENBURG THALM/SH SH upgraded shares of Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Weiss Ratings lowered Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. Finally, Zacks Research upgraded Turn Therapeutics to a “hold” rating in a research note on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Turn Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $9.00.

Turn Therapeutics Stock Up 6.0%

TTRX opened at $13.45 on Friday. The company has a market capitalization of $400.68 million and a P/E ratio of -46.38. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19. The firm’s fifty day moving average price is $9.83 and its two-hundred day moving average price is $6.35. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $26.50.

Turn Therapeutics (NASDAQ:TTRX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. On average, analysts anticipate that Turn Therapeutics will post -0.4 EPS for the current year.

Institutional Investors Weigh In On Turn Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Jefferies Financial Group Inc. acquired a new position in shares of Turn Therapeutics during the second quarter worth approximately $119,000. Bank of America Corp DE bought a new stake in shares of Turn Therapeutics during the second quarter valued at approximately $103,000. Ieq Capital LLC acquired a new stake in shares of Turn Therapeutics in the second quarter valued at approximately $1,660,000. BlackRock Inc. acquired a new stake in shares of Turn Therapeutics in the second quarter valued at approximately $282,000. Finally, Bridgewater Advisors Inc. bought a new position in Turn Therapeutics in the 2nd quarter worth approximately $242,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.